Heparins: Process-related physico-chemical and compositional characteristics, fingerprints and impurities

Summary

During the past 25 years, heparin extraction and purification processes have changed. The results of these changes are reflected by the continuous increase in potency of the International Standard for heparin. This increase is due not only to a higher purity, but also to a number of changes in the physicochemical characteristics of heparin. For long time, all these changes have been disregarded as non-critical by regulatory authorities. Heparin marketing authorisation was reviewed only two years ago and Pharmacopoeia monographs were reviewed just for the addition of new tests, mainly aimed at tackling the oversulfated chondroitin sulfate (OSCS) crisis. Currently, heparin monographs are again under revision. Such changes, different for each manufacturer, have caused a further increase in the heterogeneity of individual batches of heparin. This review aims at showing that chemical, physical and biological characteristics of heparin (such as disaccharide composition, amount of low sulfated and high sulfated sequences, molecular weight profiles [MW], activities, structural artifacts, fingerprints and glycosaminoglycans impurities) are all process-dependent and may significantly vary when different processes are used to minimise the content of dermatan sulfate. The wide heterogeneity of the physico-chemical characteristics of currently marketed heparin and the lack of suitable and shareable reference standards for the identification/quantification of process-related impurities caused, and are still causing, heated debates among scientific institutions, companies and authorities.

Keywords

Heparin - dermatan sulfate - process-related impurities

• References

• 1 Guerrini M, Beccati D, Shriver Z. et al. Oversulfated chondroitin sulfate is a major contaminant in heparin associated with adverse clinical events. Nature Biotechnology 2008; 26: 689-675.
• 2 Kishimoto TK, Viswanatan K, Ganguly T. et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. New Engl J Med 2008; 358: 1-11.
• 3 Heparin Open Microphone Web Meeting, Meeting #2, Thursday, June 12, 2008 – 11:30 a.m. to 12:30 p.m.Eastern Time. Accessed at: “http://www.usp.org/pdf/EN/hottopics/heparinPresentation.pdf” on January 12, 2009.
• 4 Pharmacopoeial Forum. 2009; 35: 1-10.
• 5 Report EMEA/276814/2008. London: 5 June 2008.
• 6 Neville GA, Mori F, Holme KR. et al. Monitoring the purity of pharmaceutical heparin preparations by high-field ¹H-NMR spectroscopy. J Pharm Sci 1989; 78 (02) 101-104.
• 7 Neville GA, Mori F, Racey TJ. et al. Chemical Composition, Particle Size Range, and Biological Activity of Some Low Molecular Weight Heparin Derivatives. J Pharm Sci 1990; 79: 339-343.
• 8 Mulloy B, Gray E, Barrowcliffe TW. Characterisation of unfractionated heparin: comparison of materials from the last 50 years. Thromb Haemost 2000; 84: 1052-1056.
• 9 Trowbridge JM, Gallo RL. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 2002; 12: 117-125.
• 10 Ofosu FA. Pharmacological actions of Sulodexide. Sem Thromb Hemost 1998; 24: 127-138.
• 11 Casu B, Guerrini M, Torri G. Structural and conformational aspects of the anticoagulant and antithrombotic activity of heparin and dermatan sulfate. Curr Pharmac Des 2004; 10: 939-949.
• 12 Mascellani G, Liverani L, Bianchini P. et al. Structure and contribution to the HCII-mediated inhibition of thrombin of naturally oversulfated sequences of dermatan sulphate. Biochem J 1993; 296: 639-659.
• 13 Mascellani G, Liverani L, Prete A. et al. Active site of dermatan sulfate for heparin cofactor II. Isolation of a nonasaccharide fragment containing four disaccaride sequences [α–L-iduronic acid 2-O-sulfate (1,3)-β-D-N-acethylglucosamine 4-sulfate]. J Carbohydr Chem 1995; 14: 1165-1177.
• 14 Mascellani G, Liverani L, Parma B. et al. Active site for heparan cofactor II in low molecular mass dermatan sulfate. Contribution to the antithrombotic activity of fractions with high affinity for heparin cofactor II. Thromb Res 1996; 84: 21-32.
• 15 Koopmann W, Ediriwickrema C, Krangel MS. Structure and function of glycosamiglycan binding site of chemokine macrophage-inflammatory protein-1β. J Immunol 1999; 163: 2120-2127.
• 16 Penc SF, Pomahac B, Winkler T. et al. Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. J Biol Chem 1998; 273: 28116-28121.
• 17 Sasisekharan R, Shriver Z, Venkataraman G. et al. Role of heparan sulfate glycosaminoglycans in cancer. Nature Review/Cancer 2002; 02: 521-528.
• 18 Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular weight heparin. Thromb Haemost 2008; 99: 807-818.
• 19 Mascellani G, Bianchini P. Non anticoagulant heparan sulfate, process for extraction from organs and pharmaceutical composition thereof. WO8904328. EP 0386053B1. 1994 Trough Esp@cenet; through CA 112. 091793/11P.
• 20 Mascellani G, Liverani L, Bianchini P. Analysis of origin of heparin and related polysaccharides by quantitation of disaccharide components. XVIII Carbohydrate Symposium. 1996 July 21–26 Milan Italy. Abstract AP49 p. 115.
• 21 Shively JE, Conrad HE. Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry 1976; 15: 3932-3942 and ibidem. Nearest neighbor analysis of heparin: identification and quantitation of the products formed by selective depolymerization procedures. Biochemistry 1976; 15: 3943–3950.
• 22 Lormeau JC, Petitou M, Choay J. Mucopolysaccharides having biological properties, preparation and method of use. US 4,500519. 1985 Through CA 98. P132290c.
• 23 Mourier P, Viskov C. Method for determining specific groups constituting heparins or low molecular weight heparins. Patent application US 2005/0119477 A1. Through CA 142. 89363P.
• 24 Volpi N, Mascellani G, Bianchini P. et al. Analytical techniques for studying structures of DS and LMW DS. Il Farmaco 1992; 47: 841-853.
• 25 Thunberg L, Bäckström G, Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 1982; 100: 393-410.
• 26 Lindahl U, Bäckström G, Thunberg L. The antithrombin binding sequence in heparin. Identification of an essential 6O-sulfate group. J Biol Chem 1983; 258: 9826-9830.
• 27 Mourier P, Viskov C. Process for oxidizing UFH and detecting presence of glycoserine. US 2005/0215519; Through CA 143. 353287/19 Patent 20051225.
• 28 Iacomini M, Casu B, Guerrini M. et al. Linkage region of heparin and heparan sulfate: detection and quantification by Nuclear magnetic resonance spectroscopy. Anal Biochem 1999; 274: 50-58.
• 29 Rey N, Perlin AS. Base catalyzed conversion of the α-L-galacturonic acid, and related reactions. Carbohydr. Res 1990; 200: 437-447.
• 30 Mascellani G, Guerrini M, Torri G. et al. Characterization of di- and monosulfated, unsaturated heparin disaccharides with terminal N-sulfated 1,6-anhydro-β-D-glucosamine or N-sulfated 1,6-anhydro- β-D-mannosamine residues. Carbohydr Res 2007; 342: 835-842.
• 31 Mourier P, Viskov C. Chromatographic analysis and sequencing approach of heparin oligosaccharides using cetyltrimethyl ammonium dynamically coated stationary phases. Anal Biochem 2004; 332: 299-313.
• 32 Bisio A, Guerrini M, Yates EA. et al. NMR identification of structural environments for 2,3 or 2,3,6 trisulfated glucosamine residues in heparin with high and no affinity for antithrombin. Glycoconj J 1997; 14: S89.
• 33 Guerrini M, Guglieri S, Casu B. et al. Antithrombin-binding octasaccharides and role of extension of the active pentasaccharide sequence in the specificity and strength of interaction. J Biol Chem 2008; 283: 26662-26675.
• 34 Vongchan P, Warda M, Toida T. et al. Structural characterization of human liver heparan sulfate. Biochim Biophys Acta 2005; 1721: 1-8.
• 35 Bianchini P, Osima B, Parma B. et al. Fractionation and structural features of two heparin families with high antithrombotic, antilipemic and anticoagulant activities. Arzneim-Forsch/Drug Res 1985; 35: 1215-1219.